Table 3.
Results of linear regression model II, showing a relationship between plasma proteins (which were showing an association with change in omega-3 FAs) with clinical outcomes at 6 months follow-up.
| Clinical outcomes | PSS | SOFAS | BACS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Protein names | Coef. | P value | 95% Conf. interval | Coef. | P value | 95% Conf. interval | Coef. | P value | 95% Conf. interval | |
| Alpha-1-antitrypsin | SERPINA1 | 0.41 | 0.78 | −2.44 to 3.27 | 0.02 | 0.99 | −2.73 to 2.77 | −0.77 | 0.55 | −3.32 to 1.77 |
| Alpha-1B-glycoprotein | A1BG | 0.79 | 0.57 | −1.94 to 3.53 | 0.05 | 0.97 | −2.59 to 2.69 | −0.50 | 0.7 | −3.08 to 2.08 |
| Apolipoprotein C-I | APOC1 | 1.03 | 0.47 | −1.80 to 3.86 | −1.22 | 0.37 | −3.94 to 1.49 | −1.16 | 0.36 | −3.68 to 1.35 |
| Apolipoprotein C-III | APOC3 | −0.98 | 0.5 | −3.82 to 1.87 | 1.30 | 0.34 | −1.40 to 4.01 | 2.85 | 0.03* | 0.36 to 5.34 |
| Apolipoprotein D | APOD | 1.17 | 0.41 | −1.62 to 3.96 | 2.77 | 0.04* | 0.13 to 5.41 | 3.87 | 0.00* | 1.25 to 6.50 |
| Apolipoprotein E | APOE | −2.15 | 0.12 | −4.87 to 0.58 | 1.37 | 0.3 | −1.24 to 3.97 | 3.09 | 0.01* | 0.71 to 5.48 |
| Apolipoprotein L1 | APOL1 | 1.23 | 0.38 | −1.52 to 3.99 | 1.13 | 0.4 | −1.51 to 3.78 | 1.96 | 0.12 | −0.49 to 4.42 |
| Caspase-14 | CASP14 | 1.84 | 0.19 | −0.95 to 4.62 | 1.08 | 0.43 | −1.60 to 3.75 | −1.29 | 0.31 | −3.81 to 1.24 |
| Coagulation factor V | F5 | −0.05 | 0.97 | −2.86 to 2.76 | 1.48 | 0.28 | −1.20 to 4.16 | 3.67 | 0.00* | 1.22 to 6.11 |
| Complement C1q subcomponent subunit B | C1QB | −0.01 | 0.99 | −2.83 to 2.80 | 0.95 | 0.49 | −1.75 to 3.64 | 3.93 | 0.00* | 1.58 to 6.28 |
| Complement C5 | C5 | 3.54 | 0.01* | 0.79 to 6.30 | −3.23 | 0.02* | −5.87 to −0.59 | −0.88 | 0.49 | −3.38 to 1.63 |
| Complement component C7 | C7 | 0.16 | 0.91 | −2.66 to 2.98 | 0.06 | 0.97 | −2.62 to 2.74 | 2.06 | 0.1 | −0.39 to 4.51 |
| Complement factor B | CFB | 0.78 | 0.58 | −2.01 to 3.58 | −1.98 | 0.15 | −4.66 to 0.71 | −3.18 | 0.02* | −5.72 to −0.63 |
| Complement factor I | CFI IF | 2.49 | 0.07 | −0.22 to 5.21 | −2.36 | 0.08 | −4.97 to 0.25 | −0.30 | 0.81 | −2.77 to 2.16 |
| Filamin A-interacting protein 1-like protein | FILIP1L | 0.18 | 0.9 | −2.56 to 2.92 | 0.84 | 0.54 | −1.84 to 3.53 | 1.20 | 0.34 | −1.28 to 3.67 |
| Galectin-3-binding protein | LGALS3BP | 0.24 | 0.87 | −2.67 to 3.16 | −0.89 | 0.53 | −3.68 to 1.91 | 0.27 | 0.85 | −2.46 to 2.99 |
| Haptoglobin | HP | 1.07 | 0.45 | −1.72 to 3.85 | −1.34 | 0.32 | −4.01 to 1.33 | −0.58 | 0.65 | −3.11 to 1.95 |
| Immunoglobulin heavy constant gamma 2 | IGHG2 | −1.83 | 0.19 | −4.56 to 0.89 | 0.81 | 0.54 | −1.80 to 3.42 | −0.85 | 0.5 | −3.32 to 1.62 |
| Immunoglobulin heavy constant gamma 4 | IGHG4 | −3.13 | 0.02* | −5.79 to −0.47 | −0.22 | 0.87 | −2.80 to 2.36 | 1.98 | 0.11 | −0.46 to 4.42 |
| Immunoglobulin heavy variable 1–18 | IGHV1-18 | 0.2 | 0.89 | −2.59 to 3.00 | −0.05 | 0.97 | −2.74 to 2.65 | 0.75 | 0.56 | −1.79 to 3.29 |
| Immunoglobulin heavy variable 3–7 | IGHV3-7 | −0.29 | 0.84 | −3.05 to 2.48 | 0.27 | 0.84 | −2.38 to 2.91 | 1.57 | 0.21 | −0.87 to 4.01 |
| Immunoglobulin kappa variable 3–20 | IGKV3-20 | −0.25 | 0.86 | −3.08 to 2.57 | 0.28 | 0.84 | −2.41 to 2.97 | 2.27 | 0.08 | −0.24 to 4.79 |
| Protein S100-A9 | S100A9 | 3.4 | 0.03* | 0.27 to 6.52 | −1.48 | 0.34 | −4.56 to 1.60 | −0.63 | 0.66 | −3.50 to 2.23 |
| Talin-1 | TLN1 | 1.02 | 0.47 | −1.74 to 3.78 | −1.95 | 0.14 | −4.58 to 0.68 | 0.40 | 0.75 | −2.04 to 2.83 |
The table shows the results of linear regression models between plasma proteins with clinical outcomes at follow-up. The models were adjusted for age, sex, and corresponding baseline protein levels. PSS Positive Symptom Severity score (based on the CAARMS assessment), SOFAS Social and Occupational Functional Assessment Scale, BACS composite score of Brief Assessment of Cognitive Function & *significant findings.